Skip to content

Study · Randomized controlled trial · n = 535 · 2020

3 results

Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.

Romera I, Conget I, Vazquez LA, Gentilella R, Lebrec J, Jódar E, Reviriego J

Journal of diabetes and its complications5 Mar 2020Cited by 1 (Europe PMC)

PMID32220551 (opens in a new tab)DOI10.1016/j.jdiacomp.2020.107575 (opens in a new tab)PepBankPUB-32220551
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In metformin- and glimepiride-treated T2DM patients, dulaglutide increased odds of reaching the fasting glucose target without hypoglycemia versus insulin glargine.

    In plain wordsIn patients with diabetes, dulaglutide increased the chance of reaching the fasting glucose target without low blood sugar versus insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFSG target without hypoglycemia at week 4
    Study

    n = 535

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · 4 weeksAs given in this study (human).

    Measurements

    Odds ratio
    1.78 ratio
    week 4

    Source sentences

    Summary
    The probability of reaching the FSG target without hypoglycemia was higher with dulaglutide than with insulin glargine at weeks 4 (OR 1.78; 95% confidence interval [CI] 1.22-2.60) and 8 (OR 1.69; 95% CI 1.15-2.48).
    2 context sentences
    Summary · context
    Two composite endpoints were used: for weeks 2-20, fasting serum glucose (FSG) <130 mg/dL (<7.2 mmol/L) without hypoglycemia (blood glucose ≤70 mg/dL [≤3.9 mmol/L] or severe hypoglycemia);
    Summary · context
    This post hoc analysis used data from a randomized, open-label study (AWARD-2; modified intention-to-treat group) in which suboptimally controlled metformin + glimepiride-treated patients received dulaglutide 1.5 mg (n = 273) or insulin glargine (n = 262).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In metformin- and glimepiride-treated T2DM patients, dulaglutide increased odds of reaching the fasting glucose target without hypoglycemia versus insulin glargine.

    In plain wordsIn patients with diabetes, dulaglutide increased the chance of reaching the fasting glucose target without low blood sugar versus insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFSG target without hypoglycemia at week 8
    Study

    n = 535

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · 8 weeksAs given in this study (human).

    Measurements

    Odds ratio
    1.69 ratio
    week 8

    Source sentences

    Summary
    The probability of reaching the FSG target without hypoglycemia was higher with dulaglutide than with insulin glargine at weeks 4 (OR 1.78; 95% confidence interval [CI] 1.22-2.60) and 8 (OR 1.69; 95% CI 1.15-2.48).
    2 context sentences
    Summary · context
    Two composite endpoints were used: for weeks 2-20, fasting serum glucose (FSG) <130 mg/dL (<7.2 mmol/L) without hypoglycemia (blood glucose ≤70 mg/dL [≤3.9 mmol/L] or severe hypoglycemia);
    Summary · context
    This post hoc analysis used data from a randomized, open-label study (AWARD-2; modified intention-to-treat group) in which suboptimally controlled metformin + glimepiride-treated patients received dulaglutide 1.5 mg (n = 273) or insulin glargine (n = 262).
  3. 03HumanRandomized controlled trialEfficacy outcome

    At week 26, HbA1c <7.0% or reduction ≥1.0%, without hypoglycemia or weight gain, occurred in 37.4% with dulaglutide versus 10.3% with glargine.

    In plain wordsMore dulaglutide patients than glargine patients met the HbA1c target or reduction threshold without low blood sugar or weight gain.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseComposite HbA1c response without hypoglycemia or weight gain
    Study

    n = 535

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · 26 weeksAs given in this study (human).

    Measurements

    Patients achieving 26-week composite endpoint
    37.4%
    dulaglutide 1.5 mg
    Patients achieving 26-week composite endpoint
    10.3%
    insulin glargine
    Odds ratio
    5.28 ratio
    dulaglutide versus insulin glargine, week 26

    Source sentences

    Summary
    The proportion of patients achieving the 26-week endpoint was higher with dulaglutide (37.4% vs. 10.3%; OR 5.28; 95% CI 3.28-8.48).
    2 context sentences
    Summary · context
    at week 26, patients with glycated hemoglobin (HbA1c) <7.0% (<53.0 mmol/mol) or reduction from baseline ≥1.0% (≥10.9 mmol/mol), no hypoglycemia (as defined above) and no weight gain.
    Summary · context
    This post hoc analysis used data from a randomized, open-label study (AWARD-2; modified intention-to-treat group) in which suboptimally controlled metformin + glimepiride-treated patients received dulaglutide 1.5 mg (n = 273) or insulin glargine (n = 262).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.